\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={A Review on Microvascular Complications in Diabetes}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2018 2018-01-15 (revised: 22 Year 2018 15 January 2018)} \def\TheID{\makeatother } \def\TheDate{2018 2018-01-15} \title{A Review on Microvascular Complications in Diabetes} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Priya Sharma} \author[2]{Neeraj Kumar} \author[3]{Amit Singh} \affil[1]{ Monad University} \renewcommand\Authands{ and } \date{\small \em Received: 12 December 2017 Accepted: 5 January 2018 Published: 15 January 2018} \maketitle \begin{abstract} Diabetes may be a chronic global health issue, that affects children's and adult both, when insulin level or resistance to insulin action becomes insufficient to control systemic glucose levels. The number of available agents to manage diabetes continues to expand rapidly; the maintenance of euglycemia by individuals with diabetes remains a substantial challenge. Many patients with type 1 (it mostly affects children's because it is a genetic disease) and type 2 (it is mostly affects adults) diabetes will ultimately experience diabetes complications. Diabetes can lead to many serious microvascular degenerative complications (e.g., retinopathy, nephropathy, and neuropathy) resulting in an increased risk of morbidity and mortality and with this significant health care system costs.Diabetic retinopathy will have an effect on the peripheral retina, that macular or each both and leading cause of visual disability and blindness in individuals with diabetic retinopathy. Diabetic neuropathy is a varity of microvascular complication that affects the nerves of individuals. Diabetic kidney disease is a very serious microvascular complication that affects the kidney. Diabetes affects many organs of the body like muscles, skin, heart, brain, and kidney. A very common risk issue for diabetes is hyperglycemia, insulin resistance, dyslipidemia, cardiovascular disease, and fleshiness. \end{abstract} \keywords{complications, diabetic retinopathy, diabetic kidney disease, diabetic neuropathy.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction}]{Introduction}\par iabetes describes a collection of chronic disorders within which insulin production is insufficient to maintain normal glucose homeostasis. Whether insulin insufficiency is due to loss of pancreatic islet beta cells or resistance to insulin action, the result the chronic elevation of systemic glucose levels, trials such as the Diabetes Control and Complications trial (for type 1 diabetes) \hyperref[b0]{[1]}. The United Kingdom Prospective Diabetes Study (for type 2 diabetes) has demonstrated the benefits of intensive management on long-term disease complications. However, the implementation of intensive management strategies has remained a challenge particularly with the increasing number of patients with diabetes worldwide, and many patients struggle to maintain euglycemia. Also, emerging evidence suggests that in some circumstances, intensive glucose control alone may be insufficient to completely prevent the complications associated with diabetes \hyperref[b1]{[2]}.\par Diabetes can lead to many sever microvascular degenerative complications (e.g., retinopathy, nephropathy, and neuropathy) resulting in an increased risk of morbidity and mortality and with this significant health care system costs. Many prospective experimental studies have made public the role of intensive glucose control in reducing the risk of microvascular complications in diabetes. A number of the necessary medication that square measure wide utilized in the treatment of T2DM square measure antidiabetic drug, sulfonylureas, and thiazolidinediones class of molecules \hyperref[b2]{[3,}\hyperref[b4]{4,}\hyperref[b5]{5]}. Dipeptidyl peptidase-4 (DPP-4) inhibitors were introduced within the treatment of T2DM in 2006 \hyperref[b6]{[6]}.\par UK Prospective Diabetes Study (UKPDS) reported that compared with the conventional group, the intensive group showed a significant risk reduction by 12\% in any diabetes-related aggregate endpoint, which was mainly due to a 25\% risk reduction in microvascular finish points \hyperref[b7]{[7]}. Moreover, this intensive glycemic management crystal rectifier to the lower rates of cardiovascular events and diabetes-related mortality ten years later \hyperref[b8]{[8]}. However, in the Korean diabetic population, the prevalence of diabetic complications remains high; the prevalence of diabetic nephropathy (DN) was 30.3\% in 2016, and that of diabetic retinopathy (DR) was 15.9\% in 2015 \hyperref[b9]{[9]}.\par USA; it absolutely was calculable that nearly 21 million Americans (or approximately 7\% of the US population) consummated the diagnostic criteria for diabetes mellitus. Diabetic retinopathy at the time of the diagnosis of diabetes is lower with type I being 0.4\% in kind I while 7.6\% in kind II \hyperref[b10]{[10]}. \section[{II.}]{II.} \section[{Microvascular Complications}]{Microvascular Complications}\par Diabetes will cause several severe microvascular degenerative complications (e.g., retinopathy, nephropathy, and neuropathy) resulting in an increased risk of morbidity and mortality and with this significant health care system costs. Hence, while, ideally, the treatment of diabetes demands a holistic approach that may address varied complications related with diabetes, the first target of achieving an adequate blood glucose level as measured by hemoglobin A1c (HbA1c) level appears still essential. In fact, in previous studies in patients with T2DM, associate between the degree of hyperglycemia and a high risk of microvascular complications have been shown \hyperref[b11]{[11,}\hyperref[b12]{12]}. \section[{Diabetic Retinopathy}]{Diabetic Retinopathy}\par DR may be a major diabetic microvascular complication that may cause minimized visual acuity and sightlessness \hyperref[b13]{[13]}. Increased vascular permeability, edema, recruitment of inflammatory cells, elevated cytokine levels, tissue damage, and revascularization have been observed in DR, implicating oxidative stress and inflammation as the key mechanisms \hyperref[b14]{[14]}.\par Diabetic retinopathy is a vision-threatening process that leads to almost 10,000 new cases of sightlessness in the US each year. It is the leading cause of sightlessness between the ages of 25 to 74 years, and is responsible for about 12\% of sightlessness in the US. It's reported within the T1DM population that children have a negligible risk of developing retinopathy during the first decade of life, even when diagnosed before age two years. In adults after seven years of T1DM, about 50\% of patients have some degree of retinopathy; while after twenty years, approximately 90\% demonstrate retinopathy \hyperref[b15]{[15,}\hyperref[b16]{16]}.\par DR affects the peripheral retina, the macula, or both and is a leading cause of visual disability and blindness in people with diabetes \hyperref[b17]{[17]}. The severity of DR ranges from non-proliferative and pre-proliferative to more severely proliferative DR, in which the abnormal growth of new vessels occurs \hyperref[b18]{[18]}. Total or partial vision loss will occur through a vitreous hemorrhage or retinal, and vision loss will occur through retinal vessel leakage and ensuant macular lump \hyperref[b19]{[19]}.\par IV. \section[{Stages Of Diabetic Retinopathy}]{Stages Of Diabetic Retinopathy}\par ? Mild non-proliferative retinopathy (Figure \hyperref[fig_1]{1}) ? Moderate non-proliferative retinopathy (Figure \hyperref[fig_2]{2})\par ? Severe non-proliferative retinopathy (Figure \hyperref[fig_3]{3}) ? Proliferative retinopathy (Figure \hyperref[fig_4]{4}) \section[{Diabetic Nephropathy}]{Diabetic Nephropathy}\par Diabetic nephropathy (DN) may be a thoughtful and progressive complication of each kind 1 DM and kind 2 DM. Diabetic nephropathy is a condition that may cause end-stage renal disease requiring dialysis and eventual transplant. Patients may initially increase microalbuminuria that can develop into gross proteinuria. Gross proteinuria is an indication of widespread microvascular disease. These patients also develop elevated blood pressures and decreased glomerular filtration, eventually leading to renal failure. In the past, diabetic nephropathy has been reported to develop in about 40\% of patients with T1DM and about 20\% of patients with T2DM \hyperref[b20]{[20]}.\par Table {\ref 1}: Different stage of kidney disease in nephropathy.\par Diabetic neuropathy is the result of a slowed motor and sensory nerve conduction that most commonly develops between 5 and ten years after the onset of disease. Neuropathy can present as peripheral sensorimotor, cranial, peripheral motor, and autonomic neuropathy. The peripheral sensorimotor neuropathy is symmetric and mostly affects the feet, leading to diminished sensation and paresthesia. The diminished sensation can cause an altered perception of foot pressures and altered foot architecture. This change can result in injury, non-healing wounds, and eventual amputations. Alternatively, diabetic neuropathy can lead to painful and debilitating hyper sensation and burning dysesthesias, which makes ambulation difficult \hyperref[b21]{[21]}. The prevalence of peripheral neuropathy in the pediatric population has been reported to range between 7\% to 57\% depending on the diagnostic criteria used, with subclinical neuropathy reported to occur in 57\% of children and adolescents with T1DM \hyperref[b22]{[22]}.\par People with diabetes also frequently have autonomic neuropathy, involuntary cardiovascular autonomic dysfunction that is manifested as abnormal vital (HR) and vascular control \hyperref[b23]{[23]}.\par Physical therapists unremarkably encounter diabetesassociated PN within the analysis and treatment of balance and movement disorders as a result of these disorders frequently have an effect on lower-extremity sensation and may cause lowerextremity pain in individuals with diabetes. Loss of lowerextremity sensation let alone impaired peripheral vascular function can contribute to lower-extremity (commonly foot) ulceration \hyperref[b24]{[24]} \section[{Pathogenesis}]{Pathogenesis}\par This schematic shows the four biochemical pathways that lead to diabetic retinopathy. DHAP, dihydroxyacetone phosphate; DAG, diacylglycerol; PKC, protein kinase C; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; AGEs, advanced glycation end products, UDP-GlcNAC, N-acetylglucosamine. \section[{VII.}]{VII.} \section[{Conclusion}]{Conclusion}\par Studies were performed of the effect of treating streptozotocin type 1 diabetic rats with vildagliptin, a Dipeptidyl peptidase IV inhibitor, on retinal, vascular and nerve dysfunction. We found that treatment with vildagliptin improved some neural, vascular and retinal complications. It is becoming clear that dipeptidyl peptidase IV inhibitors have multiple affects and may improve outcome by mechanisms unrelated to the preservation of GLP-1 or GIP \hyperref[b25]{[25]}.\begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-2.png} \caption{\label{fig_0}D}\end{figure} \begin{figure}[htbp] \noindent\textbf{1}\includegraphics[]{image-3.png} \caption{\label{fig_1}Figure 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2}\includegraphics[]{image-4.png} \caption{\label{fig_2}Figure 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3}\includegraphics[]{image-5.png} \caption{\label{fig_3}Figure 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{4}\includegraphics[]{image-6.png} \caption{\label{fig_4}Figure 4 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-7.png} \caption{\label{figure7}}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.26287539936102233\textwidth}P{0.010319488817891374\textwidth}P{0.12926517571884982\textwidth}P{0.3698722044728434\textwidth}P{0.032044728434504795\textwidth}P{0.03476038338658147\textwidth}P{0.010862619808306708\textwidth}} Stages\tabcellsep \tabcellsep \multicolumn{2}{l}{Chronic kidney disease}\tabcellsep GFR\tabcellsep \% Kidney function\\ Stage 1\tabcellsep \tabcellsep \multicolumn{2}{l}{Kidney damage with normal kidney function}\tabcellsep 90 or higher\tabcellsep 90-100\\ Stage 2\tabcellsep \tabcellsep \multicolumn{2}{l}{Kidney damage with mild loss of kidney function}\tabcellsep 89-60\tabcellsep 89-60\\ Stage 3a\tabcellsep \tabcellsep \multicolumn{2}{l}{Mild to moderate loss of kidney function}\tabcellsep 59-40\tabcellsep 59-45\\ Stage 3b\tabcellsep \tabcellsep \multicolumn{2}{l}{Moderate to severe kidney function}\tabcellsep 44-30\tabcellsep 44-30\\ Stage 4\tabcellsep \tabcellsep \multicolumn{2}{l}{Sever loss of kidney function}\tabcellsep 29-15\tabcellsep 29-15\\ Stage 5\tabcellsep \tabcellsep \multicolumn{2}{l}{Kidney failure}\tabcellsep <15\tabcellsep <15\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{b) Asymmetrical/focal and multifocal neuropathies}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Diabetic lumbosacral radiculoplexus neuropathy}\\ \tabcellsep \tabcellsep \tabcellsep (DLSRN;\tabcellsep Bruns-Garland\tabcellsep syndrome,\tabcellsep diabetic\\ \tabcellsep \tabcellsep \tabcellsep amyotrophy,\tabcellsep proximal\tabcellsep diabetic\tabcellsep neuropathy).\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Cervicobrachial radiculoplexus neuropathy Trunk}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{neuropathie(thoracic/abdominal radiculopathy) cranial}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{neuropathies Mononeuropathies (median, ulna, fibular).}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{i. Risk factors}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{There are plenty of risk factors connected}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{microvascular complications. Retinopathy, neuropathy}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{and nephropathy diabetes have many risk factors like}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{hyperglycemia, hyperinsulinemia, age, tobacco use,}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{insulin treatment, etc.}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{There is a table which explains different factors}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{for different types of diabetic complications (retinopathy}\\ \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{diabetes, neuropathy diabetes, nephropathy diabetes).}\\ D D D D )\tabcellsep \tabcellsep \tabcellsep \\ (\tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{3}{l}{a) Symmetrical polyneuropathies}\tabcellsep \\ \multicolumn{3}{l}{i. Relatively stable conditions}\tabcellsep \\ \multicolumn{4}{l}{? Symmetrical distal sensory polyneuropathy (SDSP)}\\ \multicolumn{4}{l}{Variants: acute, severe SDSP in the beginning of}\\ diabetes,\tabcellsep \multicolumn{2}{l}{pseudosyringomyelia}\tabcellsep neuropathy,\\ \multicolumn{2}{l}{pseudodiabetic}\tabcellsep neuropathy,\tabcellsep autonomic\\ neuropathies.\tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{4}{l}{? Episodic (transient) symptoms: Diabetic cachexia}\\ \multicolumn{4}{l}{neuropathy Hyperglycemic neuropathy Treatment-}\\ \multicolumn{4}{l}{induced diabetic neuropathy or insulin neuritis}\\ \multicolumn{4}{l}{chronic inflammatory demyelinating polyneuropathy}\\ \multicolumn{3}{l}{(CIDP-plus) hypoglycemic neuropathy.}\tabcellsep \end{longtable} \par {\small\itshape [Note: © 2018 Global Journals 1BA Review on Microvascular Complications in Diabetes]} \caption{\label{tab_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{} \end{longtable} \par \caption{\label{tab_1}Table 2 :}\end{figure} \backmatter \begin{bibitemlist}{1} \bibitem[ World Health Organization Diabetes]{b17}\label{b17} \textit{}, \textit{World Health Organization Diabetes} \bibitem[Nascimento ()]{b25}\label{b25} ‘(editores) Diabetes mellitus: clínica, diagnóstico e tratamento interdisciplinar’. Ojm Nascimento . \textit{Atheneu} Oliveira JEP, Milech A. (ed.) 2004. p. . (Neuropatia diabética: diagnóstico e tratamento) \bibitem[Marques and Nascimento (ed.) ()]{b26}\label{b26} \textit{(editores) Tratamento. das doenças Neurológicas. 3a ed. Rio de Janeiro: Guanabara Koogan Ltda}, W MarquesJr , O Nascimento . Melo-Souza S E. (ed.) 2013. p. . (Neuropatias diabéticas) \bibitem[Holman et al. ()]{b5}\label{b5} ‘10-year follow-up of intensive glucose control in type 2 diabetes’. R R Holman , S K Paul , M A Bethel , D R Matthews , H A Neil . \textit{N Engl J Med} 2008. 359 (15) p. . \bibitem[Holman et al. ()]{b8}\label{b8} ‘10-Year follow-up of intensive glucose control in type 2 diabetes’. R R Holman , S K Paul , M A Bethel , D R Matthews , H A Neil . \textit{N Engl J Med} 2008. 359 p. . \bibitem[Donnelly et al. ()]{b21}\label{b21} ‘ABC of arterial and venous disease: vascular complications of diabetes’. R Donnelly , A M Emslie-Smith , I D Gardner , A Morris . \textit{BMJ} 2000. 320 (7241) p. . \bibitem[Stratton et al. ()]{b4}\label{b4} ‘Association of glycaemia with macro vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study’. I M Stratton , A I Adler , H A Neil . \textit{BMJ} 2000. 321 (7258) p. . \bibitem[Diabetes fact sheet in Korea Seoul: Korean Diabetes Association (2016)]{b9}\label{b9} ‘Diabetes fact sheet in Korea’. \textit{Seoul: Korean Diabetes Association} 2016. Aug 2017. Korean Diabetes Association. 2011. \bibitem[Pirart ()]{b11}\label{b11} ‘Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3 rd and last part) (author's transl)’. J Pirart . \textit{Diabetes Metab} 1977. 3 (4) p. . \bibitem[Vinik et al. ()]{b23}\label{b23} ‘Diabetic autonomic neuropathy’. A I Vinik , R E Maser , B D Mitchell , R Freeman . \textit{Diabetes Care} 2003. 26 p. . \bibitem[Trotta et al. ()]{b22}\label{b22} ‘Diabetic neuropathy in children and adolescents’. D Trotta , A Verrotti , C Salladini , F Chiarelli . \textit{Pediatr Diabetes} 2004. 5 (1) p. . \bibitem[Frank ()]{b15}\label{b15} ‘Diabetic retinopathy’. R Frank . \textit{N Engl J Med} 2004. 350 (1) p. . \bibitem[Antonetti et al. ()]{b14}\label{b14} ‘Diabetic retinopathy: seeing beyond glucose-induced microvascular disease’. D A Antonetti , A J Barber , S K Bronson , W M Freeman , T W Gardner , Jefferson L S . \textit{Diabetes} 2006. 55 p. . \bibitem[Klein et al. ()]{b13}\label{b13} ‘Epidemiology of proliferative diabetic retinopathy’. R Klein , B E Klein , S E Moss . \textit{Diabetes Care} 1992. 15 p. . \bibitem[European Association for the Study of Diabetes (EASD) ()]{b3}\label{b3} \textit{European Association for the Study of Diabetes (EASD)}, 2012. 55 p. . \bibitem[Harding ()]{b18}\label{b18} ‘Extracts from "concise clinical evidence": diabetic retinopathy’. S Harding . \textit{BMJ} 2003. 326 p. . \bibitem[Boulton]{b24}\label{b24} ‘Foot problems in patients with diabetes mellitus’. A Boulton . \textit{Blackwell Science} Pickup J, Williams G (ed.) 1997 p. . (Textbook of Diabetes) \bibitem[Klein ()]{b12}\label{b12} ‘Hyperglycemia and microvascular and macro vascular disease in diabetes’. R Klein . \textit{Diabetes Care} 1995. 18 (2) p. . \bibitem[Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet ()]{b7}\label{b7} ‘Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)’. \textit{Lancet} 1998. 352 p. . UK Prospective Diabetes Study (UKPDS) Group \bibitem[Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet ()]{b1}\label{b1} ‘Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group’. \textit{Lancet} 1998. 352 (9131) p. . \bibitem[Nathan ()]{b20}\label{b20} ‘Long-term complications of diabetes mellitus’. D Nathan . \textit{N Engl J Med} 1993. 328 (23) p. . \bibitem[Inzucchi et al.]{b2}\label{b2} \textit{Management of hyperglycemia in type 2 diabetes: a patient-centered approach}, S E Inzucchi , R M Bergenstal , J B Buse . (Position statement of the American Diabetes Association (ADA) and the) \bibitem[Sheetz and King ()]{b19}\label{b19} ‘Molecular understanding of hyperglycemia's adverse effects for diabetic complications’. M J Sheetz , G L King . \textit{JAMA} 2002. 288 p. . \bibitem[Patel and Ghate ()]{b6}\label{b6} ‘Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors’. B D Patel , M D Ghate . \textit{Eur J Med Chem} 2014. 74 p. . \bibitem[Lueder et al. ()]{b16}\label{b16} ‘Risk of retinopathy in children with type 1 diabetes mellitus before 2 years of age’. G T Lueder , S Pradhan , N H White . \textit{Am J Ophthalmol} 2005. 140 (5) p. . \bibitem[The effect of intensive treatment of diabetes on the development and progression of long-term scomplications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med ()]{b0}\label{b0} ‘The effect of intensive treatment of diabetes on the development and progression of long-term scomplications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group’. \textit{N Engl J Med} 1993. 329 (14) p. . \bibitem[Roy et al. ()]{b10}\label{b10} ‘The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States’. M S Roy , R Klein , B J O'colmain . \textit{Arch. Ophthalmic} 2004. 122 p. . \bibitem[Nauck and El-Ouaghlidi ()]{b27}\label{b27} ‘The therapeutic actions of DPP-IV inhibition are notmediated by glucagon-like peptide-1’. M A Nauck , A El-Ouaghlidi . \textit{Diabetologia} 2005. 48 (4) p. . \end{bibitemlist} \end{document}